# US 2025/0154104 A1 · Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154104 A1
- Document ID: US20250154104A1
- Status: Published application
- Kind: A1
- Application number: 19/026,662
- Filed: 2025-01-17
- Published: 2025-05-15
- Earliest claimed: 2019-05-15
- Assignees: AlonBio Ltd.
- Applicants: AlonBio Ltd.
- Inventors: Amnon PELED; Michal ABRAHAM KARNI; Orly EIZENBERG
- Web page: https://patentgrep.com/patent/US20250154104A1

## CPC

- C07D 215/22: attached in position 2 or 4
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07D 215/26: Alcohols; Ethers thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.

## Claims

### Claim 1

A compound represented by Formula Ia and/or Ib:
wherein:
A is an alkyl being at least 4 carbon atoms in length;
B is selected from hydroxy and alkoxy;
D and G are each independently selected from hydrogen, hydroxy, alkoxy and alkyl, provided that at least one of D and G is hydrogen;
E is hydroxy;
R1 is selected from hydrogen and alkyl; and
each of R2-R5 is independently selected from hydrogen, hydroxy, halo, alkoxy, thioalkoxy, thiol, thioalkoxy and amine.

### Claim 2 (depends on 1)

The compound of claim 1, wherein B is alkoxy.

### Claim 3 (depends on 1)

The compound of claim 1, wherein one of D and G is alkoxy.

### Claim 4 (depends on 1)

The compound of claim 1, wherein when one of D and G is alkyl, said alkyl is at least 4 carbon atoms in length.

### Claim 5 (depends on 1)

The compound of claim 1, wherein each of R1-R5 is hydrogen.

### Claim 6 (depends on 1)

The compound of claim 1, represented by Formula IIa or IIb:
wherein:
A is an alkyl being at least 4 carbon atoms in length;
B is selected from hydroxy and alkoxy;
D and G are each independently selected from hydrogen, hydroxy, alkoxy and alkyl, provided that at least one of D and G is hydrogen;
R1 is selected from hydrogen and alkyl; and
each of R2-R5 is independently selected from hydrogen, hydroxy, halo, alkoxy, thioalkoxy, thiol, thioalkoxy and amine.

### Claim 7 (depends on 6)

The compound of claim 6, wherein each of R1-R5 is hydrogen.

### Claim 8 (depends on 6)

The compound of claim 6, wherein at least one of D and G is alkoxy.

### Claim 9 (depends on 6)

The compound of claim 6, wherein B is alkoxy.

### Claim 10 (depends on 1)

The compound of claim 1, being:

### Claim 11 (depends on 1)

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

### Claim 12 (depends on 11)

The method of claim 11, further comprising administering to the subject an anti-cancer agent.

### Claim 13 (depends on 1)

A method of treating skin inflammation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

### Claim 14 (depends on 1)

A method of treating a disease characterized by inflammation of the skin, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disease is selected from dermatitis, atopic dermatitis (eczema, atopy), contact dermatitis, dermatitis herpetiformis, generalized exfoliative dermatitis, seborrheic dermatitis, drug rashes, erythema multiforme, erythema nodosum, granuloma annulare, poison ivy, poison oak, toxic epidermal necrolysis, roseacae, psoriasis, acne, and a physical injury to the skin.

### Claim 16 (depends on 1)

A method of treating a disease or disorder selected from tuberculosis; HIV-1; proliferative glomerulonephritis; neural tube defects; xanthogranulomatous pyelonephritis; scleritis; rapidly progressive glomerulonephritis; pneumoconiosis; encephalitis; peritonitis; atherosclerosis; psoriasis; dengue shock syndrome; temporal arteritis; relapsing polychondritis; diabetic angiopathy; mesangial proliferative glomerulonephritis; sympathetic ophthalmia; ureteral disease; lupus nephritis; pneumonia; periapical granuloma; erdheim-chester disease; glomerulonephritis; artery disease; viral encephalitis; primary cutaneous amyloidosis; arteriosclerosis; nonspecific interstitial pneumonia; acute poststreptococcal glomerulonephritis; coronary artery disease; venezuelan equine encephalitis; diabetic macular edema; extrapulmonary tuberculosis; nephritis; rheumatoid arthritis; kawasaki disease; arthritis; malaria; obesity; psychiatric disorders; cancer; neurodegenerative disorders; age-related macular degeneration; Whim Syndrome; Cervical Adenocarcinoma; Breast Cancer; Bursitis; Tuberculosis; Intraocular Lymphoma; Cytomegalovirus Retinitis; Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Ocular Hypertension; Polyradiculoneuropathy; Dendritic Cell Tumor; Retinal Hemangioblastoma; Malaria; Endotheliitis; Leukemia; Prostatitis; Prostate Cancer; Colorectal Cancer; Chronic Lymphocytic Leukemia; Pancreatitis; Neuronitis; Lung Cancer; Osteoarthritis; Hypoxia; Adenocarcinoma; Pancreatic Cancer; Multiple Myeloma; Neuroblastoma; Myeloid Leukemia; Astrocytoma; Periodontitis; Glioblastoma; Pre-Eclampsia; Melanoma; Hepatitis; Esophagitis; Myeloma; Eclampsia; Cervicitis; Periodontal Disease; Central Nervous System Lymphoma; Sporadic Breast Cancer; Hepatocellular Carcinoma; Systemic Lupus Erythematosus; Asthma; Renal Cell Carcinoma; Myocardial Infarction; Medulloblastoma; Endometrial Cancer; Lupus Erythematosus; Esophageal Cancer; Premature Ovarian Failure; Peritonitis; Vascular Disease; Alcoholic Hepatitis; Kidney Disease; Cutaneous Leishmaniasis; Encephalitis; Alopecia Areata; Lymphoblastic Leukemia; Adenoma; Mantle Cell Lymphoma; Oligodendroglioma; Malt Lymphoma; Pertussis; Ischemia; Uveal Melanoma; Gingivitis; Pituitary Adenoma; Bronchiolitis; Neuromyelitis Optica; Mesothelioma; Alopecia; Cervical Cancer, Somatic; Glioblastoma Multiforme; Bronchiolitis Obliterans; Brain Injury; Colorectal Adenoma; Tongue Squamous Cell Carcinoma; B-Cell Lymphomas; Traumatic Brain Injury; Intravascular Large B-Cell Lymphoma; Allergic Asthma; Tick-Borne Encephalitis; Blastic Plasmacytoid Dendritic Cell; Oligoastrocytoma; Childhood Type Dermatomyositis; Renal Oncocytoma; Endometrial Adenocarcinoma; Optic Neuritis; Seminoma; Sjogren's Syndrome; Pleurisy; Neuritis; Inflammatory Bowel Disease; Cytomegalovirus Infection; Malignant Pleural Mesothelioma; Oral Squamous Cell Carcinoma; Skeletal Muscle Regeneration; Emery-Dreifuss Muscular Dystrophy, Dominant Type; fibrosis; idiopathic pulmonary fibrosis; scleroderma; cirrhosis of the liver; an infectious disease, an autoimmune disease; a hypersensitivity associated inflammation; a graft rejection; an injury; and skin inflammation, in a subject in need thereof,
the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

### Claim 17 (depends on 1)

A method of treating a disease or disorder selected from psoriasis, rheumatoid arthritis, multiple sclerosis, atherosclerosis, glomerulonephritis, epilepsy, Alzheimer's disease, brain ischemia, traumatic brain injury, type II diabetes and age-related macular degeneration (AMD), in a subject in need thereof,
the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

### Claim 18 (depends on 1)

A method of treating a disease or disorder selected from harmful angiogenesis, tumor metastasis, WHIM syndrome, Waldenstrom macroglobulinemia and opioid-induced hyperalgesia, in a subject in need thereof,
the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

### Claim 19 (depends on 1)

A method of treating a disease or disorder selected from selected from an infectious disease, an autoimmune disease, a hypersensitivity associated inflammation, a graft rejection and an injury, in a subject in need thereof,
the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1.
